Proto Script Pharmaceutical Corp. (PSCR) Financial Statements (2024 and earlier)

Company Profile

Business Address 9830 6TH STREET, SUITE 103
RANCHO CUCAMONGA, CA 91730
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 733 - Mailing, Reproduction, Commercial Art And Photography, and Stenographic Services (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
5/31/2016
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25056461712
Cash and cash equivalents25056461712
Receivables104105140247213 
Other current assets1235112 
Other undisclosed current assets(250)     
Total current assets:11619614525423212
Noncurrent Assets
Property, plant and equipment4233261513 
Other noncurrent assets7     
Total noncurrent assets:5033261513 
TOTAL ASSETS:16622917026924512
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:23018317934337
Employee-related liabilities3730211912 
Accounts payable1601311571522 
Accrued liabilities3323    
Other undisclosed accounts payable and accrued liabilities      7
Debt23869518252 
Derivative instruments and hedges, liabilities466497    
Due to related parties17171799 82
Other liabilities1271271677676 
Other undisclosed current liabilities24616175   
Total current liabilities:1,3241,05549029116189
Noncurrent Liabilities
Total liabilities:1,3241,05549029116189
Equity
Equity, attributable to parent(1,158)(826)(320)(22)84(77)
Preferred stock22    
Common stock4949344330333
Additional paid in capital7,2467,2466,953  106
Retained earnings (accumulated deficit)(8,455)(8,123)(7,617)(353)51(186)
Total equity:(1,158)(826)(320)(22)84(77)
Other undisclosed liabilities and equity      
TOTAL LIABILITIES AND EQUITY:16622917026924512

Income Statement (P&L) ($ in thousands)

9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
5/31/2016
Q4
Revenues
(Revenue, Net)
114138100214132 
Cost of revenue
(Cost of Goods and Services Sold)
(84)(31)(100)(39)(57) 
Gross profit:30107117475 
Operating expenses(274)(369)(380)(174)(143)(21)
Other undisclosed operating loss      (9)
Operating income (loss):(244)(262)(380)0(68)(30)
Nonoperating expense(88)(244)    
Other undisclosed loss from continuing operations before equity method investments, income taxes   (13,769)   
Income (loss) from continuing operations:(333)(506)(14,149)0(68)(30)
Income (loss) before gain (loss) on sale of properties:(333)(506)(14,149)0(68)(30)
Net income (loss):(333)(506)(14,149)0(68)(30)
Other undisclosed net income attributable to parent   6,885  9
Net income (loss) available to common stockholders, diluted:(333)(506)(7,264)0(68)(21)

Comprehensive Income ($ in thousands)

9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
5/31/2016
Q4
Net income (loss):(333)(506)(14,149)0(68)(30)
Comprehensive income (loss), net of tax, attributable to parent:(333)(506)(14,149)0(68)(30)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: